Bay R1005 |
|
Vaxjo ID |
41 |
|
Vaccine Adjuvant Name |
Bay R1005 |
|
Alternative Names |
N-( 2-Deoxy-2-L-leucylamino-β-D-glucopyranosyl)-N-octadecyldodecanoylamide hydroacetate |
|
Adjuvant VO ID |
VO_0001287
|
|
Description |
BAY R1005 in combination with purified virus vaccines or subunit vaccines leads to increased protection of virus-challenged mice (Vogel and Powell, 1995). |
|
Stage of Development |
Research |
|
Components |
N-(2-Deoxy-2-L-leucylamino-b-D-glucopyranosyl)-N-octadecyldodecanoylamide hydroacetate (Vogel and Powell, 1995). |
|
Molecular Weight |
726.1 + Acetate |
|
Appearance |
White lyophilizate. |
|
Storage |
Store at 2-8C in airtight containers (Vogel and Powell, 1995). |
|
Dosage |
According to a study, doses used on rats ranged from 2.5, 25, or 100 mg/kg body weight (Vogel and Powell, 1995). |
|
Function |
The increase in antibody synthesis induced by BAY R1005 is specifically dependent on the antigen and is not the result of polyclonal stimulation. BAY R 1005 acts on the proliferation of B lymphocytes as a second signal which has no effect until the antigen acts as a first signal. BAY R 1005 is capable of activating B lymphocytes without the helper function of T lymphocytes. In mice parenteral immunization with recombinant urease mixed with BAY R1005 induced strong Th1 and Th2 responses and thereby elicited better protection against Helicobacter pylori infection than adjuvants which induced a prominent Th2 type response only (Vogel and Powell, 1995). |
|
Safety |
Exploratory studies in rats (doses 2.5, 25, or 100 mg/kg body weight) on acute i.p. toxicity according to "OECD Guidelines for Testing Chemicals, No. 401": no deaths, LD5o > 100 mg/kg b.w. subacute i.v. toxicity in rats (doses 2.5, 25, or 100 mg/kg body weight) for 14 days with subsequent 4-week follow-up period to test reversibility of possible effects: no-effect level at 2.5 mg/kg b.w. (Vogel and Powell, 1995). |
| Related Vaccine(s) |
|
| References |
Vogel and Powell, 1995: Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. Pharmaceutical biotechnology. 1995; 6; 141-228. [PubMed: 7551218].
|
